Trilaciclib plus chemo for new DLBCL patients
Part of Blood & lymphatic, Cancer clinical trials.
This study tests whether adding a drug called trilaciclib to standard chemotherapy can help people with newly diagnosed Diffuse Large B-Cell Lymphoma. It aims to see if this combination keeps blood counts healthier and improves treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have a new diagnosis of Diffuse Large B-Cell Lymphoma (a type of blood cancer) that hasn't been treated yet.
- You must be in generally good health to receive the study treatment.
- You cannot have other active cancers or serious health problems like uncontrolled heart disease.
- Women who can have children must have a negative pregnancy test and agree to use birth control during and after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new treatment combination (CD-RCHOP, likely a form of chemotherapy with an antibody) for people with a high-risk type of diffuse large B-cell lymphoma that has certain genetic changes (TP53 mutation and 17p deletion). It aims to see if this approach is safe and effective for this specific group.
This trial tests a new treatment combination for people newly diagnosed with a fast-growing type of lymphoma called diffuse large B-cell lymphoma (DLBCL) that has changes in two proteins, MYC and BCL2, making it a 'double expressor' lymphoma. The goal is to see if adding another drug to standard chemo-immunotherapy can improve results.
This trial tests a new drug called lisatoclax added to the usual chemotherapy and antibody treatment for people newly diagnosed with diffuse large B-cell lymphoma (DLBCL). The goal is to see if adding this drug helps the standard treatment work better.
This study tests a new drug (TRS005) combined with standard chemotherapy (cyclophosphamide, doxorubicin, and prednisone) as a first treatment for people with CD20-positive DLBCL. The goal is to see if this combination is safe and effective in controlling the lymphoma.
This trial tests whether adding a new targeted drug called birelentinib to the standard chemotherapy combination (R-CHOP) helps people with newly diagnosed aggressive lymphoma. It aims to improve the chances of remission and reduce the risk of the lymphoma coming back.
This trial tests a new drug called TQB2825 combined with chemotherapy for people with diffuse large B-cell lymphoma (DLBCL) that has come back or not responded to at least one prior treatment. It aims to see if this combination can help when other treatments haven't worked and stem cell transplant is not an option.
Hear when a new DLBCL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.